p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Malignant Lymphoma Clinical Trial

Official title:

The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01789060
• Other study ID #: 2013-01-047
• Status: Completed
• Phase: N/A
• First received: February 7, 2013
• Last updated: February 7, 2013
• Start date: December 2012
• Est. completion date: February 2013

Study information

• Verified date: February 2013
• Source: Samsung Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: South Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Description:

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B [PKB]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 262
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 17 Years to 90 Years

Eligibility

Inclusion Criteria:

1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;

2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion Criteria:

1. Primary central nervous system lymphoma was excluded in this study

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lymphoma
• Malignant Lymphoma
• P13K-AKT Pathway Deregulation

Intervention

Other:
• p-AKT immunohistochemical staining
p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Subgroup analysis of overall survival according to International Prognostic Index risk groups		study entry	No
Primary	Difference of overall survival according to p-AKT status in malignant lymphoma		study entry	No
Secondary	Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)		study entry	No